<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Crect width='32' height='32' rx='6' fill='%230f2340'/%3E%3Cpath d='M 22 4 C 3 4 3 28 22 28' fill='none' stroke='%233d9e9e' stroke-width='2.5' stroke-linecap='round'/%3E%3Cpath d='M 22 4 C 3 4 3 28 22 28' fill='none' stroke='%23c8a96e' stroke-width='5' stroke-dasharray='7 9999' stroke-dashoffset='-12' stroke-linecap='round'/%3E%3C/svg%3E" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Clinical Trials | Dr. Chee Wai Wong ‚Äî Vitreoretinal Surgeon, Singapore</title>
  <meta name="description" content="Dr. Chee Wai Wong serves as site principal investigator for clinical trials in vitreoretinal disease, including the Roche POYANG study of Vabysmo for pathologic myopia-related choroidal neovascularisation." />
  <meta name="keywords" content="clinical trials Singapore, POYANG trial, faricimab trial, pathologic myopia CNV trial, Vabysmo clinical study, retinal clinical research Singapore, Dr Chee Wai Wong research" />
  <meta property="og:type" content="website" />
  <meta property="og:title" content="Clinical Trials | Dr. Chee Wai Wong ‚Äî Vitreoretinal Surgeon, Singapore" />
  <meta property="og:description" content="Dr. Chee Wai Wong serves as site principal investigator for clinical trials in vitreoretinal disease, including the Roche POYANG study of Vabysmo for pathologic myopia-related choroidal neovascularisation." />
  <meta property="og:url" content="https://cheewaiwong.com/clinical-trials.html" />
  <meta property="og:site_name" content="Dr. Chee Wai Wong" />
  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Clinical Trials | Dr. Chee Wai Wong" />
  <meta name="twitter:description" content="Dr. Chee Wai Wong serves as site principal investigator for clinical trials in vitreoretinal disease, including the Roche POYANG study." />
  <link rel="canonical" href="https://cheewaiwong.com/clinical-trials.html" />
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:ital,wght@0,300;0,400;0,600;1,300;1,400&family=DM+Sans:wght@300;400;500&display=swap" rel="stylesheet" />
  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    :root {
      --navy: #0f2340; --teal: #2a7c7c; --teal-light: #3d9e9e;
      --gold: #c8a96e; --cream: #faf7f2; --warm-white: #fff8f0;
      --text: #1a2e3b; --muted: #6b7f8a; --border: rgba(15,35,64,0.1);
    }
    html { scroll-behavior: smooth; }
    body { font-family: 'DM Sans', sans-serif; background: var(--cream); color: var(--text); line-height: 1.7; }

    #navbar { position: fixed; top: 0; left: 0; right: 0; z-index: 200; display: flex; align-items: center; justify-content: space-between; padding: 1.25rem 4rem; background: rgba(250,247,242,0.96); backdrop-filter: blur(12px); border-bottom: 1px solid var(--border); }
    .nav-logo { font-family: 'Cormorant Garamond', serif; font-size: 1.2rem; font-weight: 600; color: var(--navy); text-decoration: none; }
    .nav-logo span { color: var(--teal); }
    .nav-links { display: flex; gap: 2.5rem; list-style: none; }
    .nav-links a { font-size: 0.82rem; font-weight: 500; letter-spacing: 0.08em; text-transform: uppercase; color: var(--muted); text-decoration: none; transition: color 0.2s; }
    .nav-links a:hover, .nav-links a.active { color: var(--teal); }
    .nav-cta { background: var(--navy) !important; color: #fff !important; padding: 0.55rem 1.4rem; border-radius: 2rem; }

    /* HERO */
    .hero { background: var(--navy); padding: 8rem 4rem 5.5rem; position: relative; overflow: hidden; }
    .hero::before { content: ''; position: absolute; top: -80px; right: -60px; width: 500px; height: 500px; border-radius: 50%; background: radial-gradient(circle, rgba(200,169,110,0.08) 0%, transparent 65%); }
    .hero::after { content: ''; position: absolute; bottom: -60px; left: 8%; width: 320px; height: 320px; border-radius: 50%; background: radial-gradient(circle, rgba(42,124,124,0.1) 0%, transparent 65%); }
    .hero-inner { max-width: 1100px; margin: 0 auto; position: relative; z-index: 1; }
    .hero-eyebrow { font-size: 0.68rem; font-weight: 700; letter-spacing: 0.18em; text-transform: uppercase; color: var(--teal-light); margin-bottom: 1rem; }
    .hero h1 { font-family: 'Cormorant Garamond', serif; font-size: clamp(2.4rem, 5vw, 3.8rem); font-weight: 300; color: #fff; line-height: 1.08; margin-bottom: 1.25rem; }
    .hero h1 strong { font-weight: 600; }
    .hero .lead { font-size: 1rem; font-weight: 300; color: rgba(255,255,255,0.5); line-height: 1.75; max-width: 640px; }

    /* SECTION STRUCTURE */
    .section { max-width: 1100px; margin: 0 auto; padding: 4rem 4rem 0; }
    .section:last-of-type { padding-bottom: 5rem; }
    .section-label { font-size: 0.68rem; font-weight: 700; letter-spacing: 0.15em; text-transform: uppercase; color: var(--teal); margin-bottom: 0.6rem; display: flex; align-items: center; gap: 0.75rem; }
    .section-label::after { content: ''; flex: 1; height: 1px; background: var(--border); }
    .section-title { font-family: 'Cormorant Garamond', serif; font-size: 1.85rem; font-weight: 400; color: var(--navy); margin-bottom: 0.75rem; }
    .section-intro { font-size: 0.92rem; color: var(--muted); font-weight: 300; line-height: 1.75; max-width: 720px; margin-bottom: 2rem; }

    /* ROLE STRIP */
    .role-strip { background: #fff; border: 1px solid var(--border); border-radius: 1rem; padding: 1.75rem 2rem; display: flex; align-items: flex-start; gap: 1.5rem; margin-bottom: 0; }
    .role-icon { flex-shrink: 0; width: 48px; height: 48px; background: rgba(42,124,124,0.08); border-radius: 12px; display: flex; align-items: center; justify-content: center; }
    .role-body h3 { font-family: 'Cormorant Garamond', serif; font-size: 1.15rem; font-weight: 400; color: var(--navy); margin-bottom: 0.35rem; }
    .role-body p { font-size: 0.88rem; color: var(--muted); font-weight: 300; line-height: 1.7; }

    /* TRIAL CARD */
    .trial-card { background: #fff; border: 1px solid var(--border); border-radius: 1rem; overflow: hidden; margin-bottom: 1.5rem; }
    .trial-card-header { background: var(--navy); padding: 2rem 2.25rem; position: relative; overflow: hidden; }
    .trial-card-header::after { content: ''; position: absolute; top: -40px; right: -40px; width: 220px; height: 220px; border-radius: 50%; background: radial-gradient(circle, rgba(200,169,110,0.1) 0%, transparent 65%); }
    .trial-header-top { display: flex; align-items: flex-start; justify-content: space-between; gap: 1.5rem; flex-wrap: wrap; margin-bottom: 1rem; position: relative; z-index: 1; }
    .trial-acronym { font-family: 'Cormorant Garamond', serif; font-size: 2.2rem; font-weight: 600; color: #fff; letter-spacing: 0.04em; line-height: 1; }
    .trial-sponsor { display: flex; align-items: center; gap: 0.5rem; }
    .trial-sponsor-label { font-size: 0.65rem; font-weight: 700; letter-spacing: 0.12em; text-transform: uppercase; color: rgba(255,255,255,0.35); }
    .trial-sponsor-name { font-size: 0.8rem; font-weight: 500; color: rgba(255,255,255,0.65); }
    .trial-official-title { font-size: 0.82rem; color: rgba(255,255,255,0.45); font-weight: 300; line-height: 1.6; max-width: 820px; position: relative; z-index: 1; }
    .trial-badges { display: flex; gap: 0.6rem; flex-wrap: wrap; margin-top: 1.25rem; position: relative; z-index: 1; }
    .trial-badge { font-size: 0.65rem; font-weight: 700; letter-spacing: 0.1em; text-transform: uppercase; padding: 0.28rem 0.85rem; border-radius: 2rem; }
    .badge-closed { background: rgba(200,169,110,0.18); color: var(--gold); border: 1px solid rgba(200,169,110,0.3); }
    .badge-phase { background: rgba(61,158,158,0.18); color: var(--teal-light); border: 1px solid rgba(61,158,158,0.3); }
    .badge-nct { background: rgba(255,255,255,0.08); color: rgba(255,255,255,0.45); border: 1px solid rgba(255,255,255,0.12); font-weight: 400; letter-spacing: 0.05em; text-transform: none; }

    .trial-card-body { padding: 2rem 2.25rem; }
    .trial-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 2rem; margin-bottom: 2rem; }
    .trial-field-label { font-size: 0.65rem; font-weight: 700; letter-spacing: 0.12em; text-transform: uppercase; color: var(--teal); margin-bottom: 0.35rem; }
    .trial-field-value { font-size: 0.9rem; color: var(--text); font-weight: 400; line-height: 1.6; }
    .trial-field-value.muted { color: var(--muted); font-weight: 300; }
    .trial-divider { height: 1px; background: var(--border); margin: 1.75rem 0; }

    /* ELIGIBILITY */
    .eligibility-cols { display: grid; grid-template-columns: 1fr 1fr; gap: 1.5rem; }
    .elig-block { background: var(--cream); border-radius: 0.75rem; padding: 1.25rem 1.5rem; }
    .elig-block h4 { font-size: 0.72rem; font-weight: 700; letter-spacing: 0.12em; text-transform: uppercase; margin-bottom: 0.85rem; }
    .elig-block h4.include { color: var(--teal); }
    .elig-block h4.exclude { color: #a07840; }
    .elig-list { list-style: none; display: flex; flex-direction: column; gap: 0.55rem; }
    .elig-list li { font-size: 0.84rem; color: var(--muted); font-weight: 300; line-height: 1.5; display: flex; gap: 0.6rem; align-items: flex-start; }
    .elig-list li::before { flex-shrink: 0; font-weight: 700; margin-top: 0.05em; }
    .elig-list.include li::before { content: '+'; color: var(--teal); }
    .elig-list.exclude li::before { content: '‚àí'; color: #a07840; }

    /* WHAT PARTICIPATION INVOLVES */
    .participation-steps { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1px; background: var(--border); border-radius: 1rem; overflow: hidden; }
    .p-step { background: #fff; padding: 1.5rem 1.5rem; }
    .p-step-num { font-family: 'Cormorant Garamond', serif; font-size: 2rem; font-weight: 300; color: rgba(42,124,124,0.2); line-height: 1; margin-bottom: 0.5rem; }
    .p-step h4 { font-size: 0.88rem; font-weight: 500; color: var(--navy); margin-bottom: 0.4rem; }
    .p-step p { font-size: 0.82rem; color: var(--muted); font-weight: 300; line-height: 1.65; }

    /* DISCLAIMER BLOCK */
    .disclaimer-block { background: rgba(200,169,110,0.06); border: 1px solid rgba(200,169,110,0.2); border-radius: 1rem; padding: 1.5rem 1.75rem; display: flex; gap: 1.25rem; align-items: flex-start; }
    .disclaimer-icon { flex-shrink: 0; color: var(--gold); margin-top: 0.1rem; }
    .disclaimer-block p { font-size: 0.84rem; color: var(--muted); font-weight: 300; line-height: 1.75; }

    /* CTA */
    .enquiry-section { background: var(--navy); padding: 4rem; margin-top: 4rem; }
    .enquiry-inner { max-width: 1100px; margin: 0 auto; display: grid; grid-template-columns: 1fr 1fr; gap: 5rem; align-items: center; }
    .enquiry-inner h2 { font-family: 'Cormorant Garamond', serif; font-size: 2rem; font-weight: 300; color: #fff; margin-bottom: 0.75rem; }
    .enquiry-inner h2 strong { font-weight: 600; }
    .enquiry-inner p { font-size: 0.92rem; color: rgba(255,255,255,0.45); font-weight: 300; line-height: 1.75; margin-bottom: 1.5rem; }
    .enquiry-bullets { list-style: none; }
    .enquiry-bullets li { font-size: 0.88rem; color: rgba(255,255,255,0.55); font-weight: 300; padding: 0.4rem 0; display: flex; gap: 0.75rem; align-items: flex-start; }
    .enquiry-bullets li::before { content: '‚Üí'; color: var(--teal-light); flex-shrink: 0; }
    .enquiry-contact { background: rgba(255,255,255,0.05); border: 1px solid rgba(255,255,255,0.1); border-radius: 1rem; padding: 2rem; }
    .enquiry-contact h3 { font-family: 'Cormorant Garamond', serif; font-size: 1.3rem; color: #fff; font-weight: 400; margin-bottom: 1.25rem; }
    .enq-row { padding: 0.75rem 0; border-bottom: 1px solid rgba(255,255,255,0.08); display: flex; gap: 1rem; align-items: flex-start; }
    .enq-row:last-child { border-bottom: none; padding-bottom: 0; }
    .enq-icon { font-size: 1rem; flex-shrink: 0; }
    .enq-label { font-size: 0.68rem; font-weight: 700; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(255,255,255,0.3); margin-bottom: 0.15rem; }
    .enq-value { font-size: 0.88rem; color: rgba(255,255,255,0.7); font-weight: 300; }
    .enq-value a { color: var(--teal-light); text-decoration: none; }
    .btn-gold { display: inline-block; background: var(--gold); color: var(--navy); padding: 0.85rem 2.25rem; border-radius: 3rem; font-size: 0.88rem; font-weight: 600; text-decoration: none; transition: all 0.25s; margin-top: 1.5rem; }
    .btn-gold:hover { background: #d9bf91; transform: translateY(-2px); }

    footer { background: #07141f; color: rgba(255,255,255,0.35); padding: 2rem 4rem; display: flex; justify-content: space-between; align-items: center; font-size: 0.8rem; flex-wrap: wrap; gap: 1rem; }
    footer a { color: rgba(255,255,255,0.35); text-decoration: none; }
    footer a:hover { color: var(--teal-light); }
    .wa-float { position: fixed; bottom: 28px; right: 28px; z-index: 500; width: 50px; height: 50px; background: #25d366; border-radius: 50%; display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 18px rgba(37,211,102,0.38); text-decoration: none; transition: background 0.2s, transform 0.2s; }
    .wa-float:hover { background: #20bd5a; transform: translateY(-2px); }

    @media (max-width: 960px) {
      #navbar { padding: 1rem 1.5rem; } .nav-links { display: none; }
      .hero { padding: 7rem 1.5rem 4rem; }
      .section { padding: 3rem 1.5rem 0; }
      .trial-grid { grid-template-columns: 1fr; gap: 1.25rem; }
      .eligibility-cols { grid-template-columns: 1fr; }
      .participation-steps { grid-template-columns: 1fr; }
      .enquiry-section { padding: 3rem 1.5rem; }
      .enquiry-inner { grid-template-columns: 1fr; gap: 2.5rem; }
      footer { flex-direction: column; text-align: center; padding: 1.5rem; }
    }
  </style>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-KGBW3DHSCL"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
    gtag('config', 'G-KGBW3DHSCL');
  </script>
</head>
<body>

<nav id="navbar">
  <a class="nav-logo" href="index.html">Dr. <span>Chee Wai</span> Wong</a>
  <ul class="nav-links">
    <li><a href="index.html#about">About</a></li>
    <li><a href="index.html#services">Services</a></li>
    <li><a href="index.html#education">Patient Info</a></li>
    <li><a href="index.html#blog">Insights</a></li>
    <li><a href="media.html">Media</a></li>
    <li><a href="fees.html">Fees</a></li>
    <li><a href="clinical-trials.html" class="active">Research</a></li>
    <li><a href="innovations.html">Innovation</a></li>
    <li><a href="index.html#contact" class="nav-cta">Book Appointment</a></li>
  </ul>
</nav>

<section class="hero">
  <div class="hero-inner">
    <p class="hero-eyebrow">Clinical Research</p>
    <h1>Advancing retinal care<br><strong>through research.</strong></h1>
    <p class="lead">Dr. Wong participates in international clinical trials as a site principal investigator, bringing access to investigational therapies to patients at Asia Pacific Eye Centre, Gleneagles Hospital, Singapore.</p>
  </div>
</section>

<!-- ROLE -->
<div class="section" style="padding-top:4rem;">
  <p class="section-label">Dr. Wong's research role</p>
  <div class="role-strip">
    <div class="role-icon">
      <svg width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="#2a7c7c" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round">
        <path d="M9 3H5a2 2 0 00-2 2v4m6-6h10a2 2 0 012 2v4M9 3v18m0 0h10a2 2 0 002-2V9M9 21H5a2 2 0 01-2-2V9m0 0h18"/>
      </svg>
    </div>
    <div class="role-body">
      <h3>Site Principal Investigator</h3>
      <p>As a site PI, Dr. Wong is responsible for the conduct of clinical trials at Asia Pacific Eye Centre in accordance with ICH Good Clinical Practice guidelines. This includes patient recruitment and consent, protocol adherence, safety monitoring, and data integrity. Participation in trials is entirely voluntary and does not affect access to standard clinical care.</p>
    </div>
  </div>
</div>

<!-- ACTIVE / RECENT TRIALS -->
<div class="section" style="padding-top:3.5rem;">
  <p class="section-label">Trials</p>
  <p class="section-title">Current & recent studies</p>
  <p class="section-intro">The following trial has been conducted at this site. Recruitment is now closed, but patients with pathologic myopia are encouraged to speak with Dr. Wong about current treatment options and any future study opportunities.</p>

  <!-- POYANG TRIAL CARD -->
  <div class="trial-card">
    <div class="trial-card-header">
      <div class="trial-header-top">
        <div>
          <div class="trial-acronym">POYANG</div>
        </div>
        <div class="trial-sponsor" style="flex-direction:column; align-items:flex-end;">
          <span class="trial-sponsor-label">Sponsor</span>
          <span class="trial-sponsor-name">Hoffmann-La Roche</span>
        </div>
      </div>
      <p class="trial-official-title">A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia</p>
      <div class="trial-badges">
        <span class="trial-badge badge-closed">Recruitment closed</span>
        <span class="trial-badge badge-phase">Phase III</span>
        <span class="trial-badge badge-nct">NCT06176352</span>
      </div>
    </div>

    <div class="trial-card-body">

      <!-- KEY DETAILS GRID -->
      <div class="trial-grid">
        <div>
          <p class="trial-field-label">Investigational drug</p>
          <p class="trial-field-value">Faricimab (Vabysmo) 6 mg, intravitreal injection ‚Äî a bispecific antibody targeting both VEGF-A and Ang-2</p>
        </div>
        <div>
          <p class="trial-field-label">Comparator</p>
          <p class="trial-field-value">Ranibizumab 0.5 mg, intravitreal injection ‚Äî standard-of-care anti-VEGF agent</p>
        </div>
        <div>
          <p class="trial-field-label">Condition studied</p>
          <p class="trial-field-value">Choroidal neovascularisation (CNV) secondary to pathologic myopia, in treatment-na√Øve patients</p>
        </div>
        <div>
          <p class="trial-field-label">Study design</p>
          <p class="trial-field-value">Randomized, triple-masked, parallel-group, active-comparator controlled. Pro re nata (as-needed) dosing after loading injection.</p>
        </div>
        <div>
          <p class="trial-field-label">Primary endpoint</p>
          <p class="trial-field-value">Change in best-corrected visual acuity (BCVA, ETDRS letters) averaged over weeks 4, 8, and 12 from baseline</p>
        </div>
        <div>
          <p class="trial-field-label">Enrolled / timeline</p>
          <p class="trial-field-value">280 participants globally &middot; Study start: March 2024 &middot; Primary completion: September 2025 &middot; Final completion: May 2026</p>
        </div>
      </div>

      <div class="trial-divider"></div>

      <!-- ELIGIBILITY -->
      <p class="trial-field-label" style="margin-bottom:1rem;">Key eligibility criteria</p>
      <div class="eligibility-cols">
        <div class="elig-block">
          <h4 class="include">Inclusion</h4>
          <ul class="elig-list include">
            <li>Adults aged 18 years or older</li>
            <li>High myopia greater than ‚àí6 diopters</li>
            <li>Active CNV with confirmed leakage on imaging</li>
            <li>Best-corrected visual acuity 24‚Äì78 ETDRS letters (approximately 6/7.5 to counting fingers)</li>
            <li>Treatment-na√Øve ‚Äî no prior CNV therapy in the study eye</li>
          </ul>
        </div>
        <div class="elig-block">
          <h4 class="exclude">Exclusion</h4>
          <ul class="elig-list exclude">
            <li>Prior intravitreal treatment for CNV in the study eye</li>
            <li>Uncontrolled systemic hypertension</li>
            <li>Recent stroke or myocardial infarction (within 6 months)</li>
            <li>Pregnancy or breastfeeding</li>
            <li>Uncontrolled glaucoma in the study eye</li>
          </ul>
        </div>
      </div>

      <div class="trial-divider"></div>

      <!-- LINKS -->
      <div style="display:flex; gap:1rem; flex-wrap:wrap; align-items:center;">
        <a href="https://clinicaltrials.gov/study/NCT06176352" target="_blank" rel="noopener" style="display:inline-flex; align-items:center; gap:0.4rem; font-size:0.82rem; font-weight:500; color:var(--teal); text-decoration:none; padding:0.45rem 1.1rem; border-radius:2rem; border:1px solid rgba(42,124,124,0.25); background:#fff; transition:all 0.2s;">
          <svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round"><path d="M18 13v6a2 2 0 01-2 2H5a2 2 0 01-2-2V8a2 2 0 012-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg>
          ClinicalTrials.gov ‚Äî NCT06176352
        </a>
        <a href="https://forpatients.roche.com/en/trials/eye-disorder/choroidal-neovascularization/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-11547.html" target="_blank" rel="noopener" style="display:inline-flex; align-items:center; gap:0.4rem; font-size:0.82rem; font-weight:500; color:var(--teal); text-decoration:none; padding:0.45rem 1.1rem; border-radius:2rem; border:1px solid rgba(42,124,124,0.25); background:#fff; transition:all 0.2s;">
          <svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round"><path d="M18 13v6a2 2 0 01-2 2H5a2 2 0 01-2-2V8a2 2 0 012-2h6"/><polyline points="15 3 21 3 21 9"/><line x1="10" y1="14" x2="21" y2="3"/></svg>
          Roche For Patients ‚Äî POYANG Study
        </a>
      </div>

    </div>
  </div>

  <div class="disclaimer-block">
    <div class="disclaimer-icon">
      <svg width="18" height="18" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="12" y1="8" x2="12" y2="12"/><line x1="12" y1="16" x2="12.01" y2="16"/></svg>
    </div>
    <p>Recruitment for the POYANG study is now closed. If you have pathologic myopia with suspected CNV, please book a consultation. Dr. Wong can assess your condition and discuss all available treatment options, including any new trials that may open in future.</p>
  </div>
</div>

<!-- WHAT PARTICIPATION INVOLVES -->
<div class="section" style="padding-top:3.5rem; padding-bottom:5rem;">
  <p class="section-label">About clinical trials</p>
  <p class="section-title">What participation involves</p>
  <p class="section-intro">Clinical trial participants receive close monitoring and access to investigational treatments at no cost. Participation is always voluntary ‚Äî you can withdraw at any time without it affecting your regular care.</p>

  <div class="participation-steps">
    <div class="p-step">
      <div class="p-step-num">01</div>
      <h4>Screening & consent</h4>
      <p>You will be assessed to confirm eligibility. A study coordinator will explain the protocol, risks, and benefits in detail. You will have time to consider before signing a consent form.</p>
    </div>
    <div class="p-step">
      <div class="p-step-num">02</div>
      <h4>Treatment & monitoring</h4>
      <p>You will receive either the investigational drug or an approved comparator, with scheduled clinic visits for assessments including visual acuity testing and retinal imaging.</p>
    </div>
    <div class="p-step">
      <div class="p-step-num">03</div>
      <h4>Follow-up & safety</h4>
      <p>The study team monitors your response and safety throughout. Any side effects are recorded and reported. You may withdraw from the trial at any time, for any reason.</p>
    </div>
  </div>
</div>

<!-- CTA -->
<div class="enquiry-section">
  <div class="enquiry-inner">
    <div>
      <h2>Interested in<br><strong>future trials?</strong></h2>
      <p>If you have a retinal condition and are interested in being considered for future studies, contact the clinic. We can discuss whether your condition may make you eligible for upcoming trials and keep you informed as new studies open.</p>
      <ul class="enquiry-bullets">
        <li>No obligation to participate</li>
        <li>Investigational treatments provided at no cost</li>
        <li>Close monitoring throughout the study period</li>
        <li>Does not affect access to standard care</li>
      </ul>
      <a href="index.html#contact" class="btn-gold">Contact the Clinic</a>
    </div>
    <div class="enquiry-contact">
      <h3>Get in touch</h3>
      <div class="enq-row">
        <span class="enq-icon">üìû</span>
        <div>
          <p class="enq-label">Phone / WhatsApp</p>
          <p class="enq-value"><a href="tel:+6592357063">+65 9235 7063</a></p>
        </div>
      </div>
      <div class="enq-row">
        <span class="enq-icon">‚úâÔ∏è</span>
        <div>
          <p class="enq-label">Email</p>
          <p class="enq-value"><a href="mailto:contact@asiapacificeyecentre.com.sg">contact@asiapacificeyecentre.com.sg</a></p>
        </div>
      </div>
      <div class="enq-row">
        <span class="enq-icon">üìç</span>
        <div>
          <p class="enq-label">Location</p>
          <p class="enq-value">Asia Pacific Eye Centre<br>Gleneagles Hospital, Singapore</p>
        </div>
      </div>
      <div class="enq-row">
        <span class="enq-icon">üïê</span>
        <div>
          <p class="enq-label">Clinic hours</p>
          <p class="enq-value">Mon ‚Äì Fri: 9am ‚Äì 5pm<br>Sat: 9am ‚Äì 1pm</p>
        </div>
      </div>
    </div>
  </div>
</div>

<footer>
  <span>¬© 2026 Dr. Chee Wai Wong ¬∑ Asia Pacific Eye Centre, Gleneagles Hospital, Singapore</span>
  <span>
    <a href="index.html#about">About</a> ¬∑
    <a href="index.html#blog">Insights</a> ¬∑
    <a href="media.html">Media</a> ¬∑
    <a href="fees.html">Fees</a> ¬∑
    <a href="clinical-trials.html">Research</a> ¬∑
    <a href="innovations.html">Innovation</a> ¬∑
    <a href="index.html#contact">Contact</a>
  </span>
</footer>

<a href="https://wa.me/6592357063" class="wa-float" target="_blank" rel="noopener" aria-label="WhatsApp the clinic">
  <svg width="26" height="26" viewBox="0 0 24 24" fill="#fff" xmlns="http://www.w3.org/2000/svg"><path d="M17.472 14.382c-.297-.149-1.758-.867-2.03-.967-.273-.099-.471-.148-.67.15-.197.297-.767.966-.94 1.164-.173.199-.347.223-.644.075-.297-.15-1.255-.463-2.39-1.475-.883-.788-1.48-1.761-1.653-2.059-.173-.297-.018-.458.13-.606.134-.133.298-.347.446-.52.149-.174.198-.298.298-.497.099-.198.05-.371-.025-.52-.075-.149-.669-1.612-.916-2.207-.242-.579-.487-.5-.669-.51-.173-.008-.371-.01-.57-.01-.198 0-.52.074-.792.372-.272.297-1.04 1.016-1.04 2.479 0 1.462 1.065 2.875 1.213 3.074.149.198 2.096 3.2 5.077 4.487.709.306 1.262.489 1.694.625.712.227 1.36.195 1.871.118.571-.085 1.758-.719 2.006-1.413.248-.694.248-1.289.173-1.413-.074-.124-.272-.198-.57-.347m-5.421 7.403h-.004a9.87 9.87 0 01-5.031-1.378l-.361-.214-3.741.982.998-3.648-.235-.374a9.86 9.86 0 01-1.51-5.26c.001-5.45 4.436-9.884 9.888-9.884 2.64 0 5.122 1.03 6.988 2.898a9.825 9.825 0 012.893 6.994c-.003 5.45-4.437 9.884-9.885 9.884m8.413-18.297A11.815 11.815 0 0012.05 0C5.495 0 .16 5.335.157 11.892c0 2.096.547 4.142 1.588 5.945L.057 24l6.305-1.654a11.882 11.882 0 005.683 1.448h.005c6.554 0 11.89-5.335 11.893-11.893a11.821 11.821 0 00-3.48-8.413z"/></svg>
</a>

</body>
</html>
